Skip to main content
Fig. 3 | Pediatric Rheumatology

Fig. 3

From: Tocilizumab for treating mevalonate kinase deficiency and TNF receptor-associated periodic syndrome: a case series and literature review

Fig. 3

(A) The mutation in the TNFRSF1A gene (NM 0010 65; exon3): c.295T > C, p.Cys99Arg, which was a spontaneous mutation. (B) ESR, CRP, WBC, IL-6, and TNF-α levels before and after treatment of tocilizumab. Arrow B indicates the first administration of tocilizumab (240 mg every three weeks). After treatment of tocilizumab, ESR, CRP, WBC, IL-6, and TNF-α return to normal in the TRAPS patient

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096